series-c-plus
Stage
1
Investors
About
Coherus Oncology develops next-generation combination immuno-oncology therapies targeting the tumor microenvironment, including FDA-approved anti-PD-1 treatment for nasopharyngeal carcinoma.
Explore Coherus Oncology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.